A phase I study is currently testing Alpelisib with a potent, oral bioavailable selective estrogen receptor degrader (SERD), LSZ102 in advanced or metastatic ER+ breast cancer patients progressed after endocrine therapy. This evidence concerns the gene ESR1 and breast cancer.